Incyte (INCY) Accounts Payables (2010 - 2026)
Incyte's (INCY) quarterly Accounts Payables came in at $250.4 million in Q2 2026, up 3.86% YoY from $241.1 million in Q2 2025, and up 9.53% on a QoQ basis from $228.6 million in Q1 2026.
Incyte (INCY) Accounts Payables (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Accounts Payables data on file, last reported at $250.4 million in Q2 2026.
- Quarterly Accounts Payables rose 3.86% year-over-year to $250.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $250.4 million (up 3.86% YoY) and the FY2025 annual result came in at $209.9 million, up 6.32% from the prior year.
- Accounts Payables rose to $250.4 million in Q2 2026, from $228.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $277.5 million in Q4 2022 to a low of $55.6 million in Q1 2023.
- A 5-year average of $179.7 million and a median of $175.3 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 63.53% — and 2024, when it jumped 195.22%.
- Tracing INCY's Accounts Payables over 5 years: stood at $277.5 million in 2022, then plunged by 60.51% to $109.6 million in 2023, then surged by 80.17% to $197.5 million in 2024, then rose by 6.32% to $209.9 million in 2025, then grew by 19.27% to $250.4 million in 2026.
- The last three Accounts Payables figures came in at $250.4 million (Q2 2026), $228.6 million (Q1 2026), and $209.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 250.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 250.40 Mn |
| Mar 31, 2026 | 228.62 Mn |
| Dec 31, 2025 | 209.94 Mn |
| Sep 30, 2025 | 171.93 Mn |
| Jun 30, 2025 | 241.09 Mn |
| Mar 31, 2025 | 195.54 Mn |
| Dec 31, 2024 | 197.47 Mn |
| Sep 30, 2024 | 178.71 Mn |
| Jun 30, 2024 | 148.17 Mn |
| Mar 31, 2024 | 164.24 Mn |
| Dec 31, 2023 | 109.60 Mn |
| Sep 30, 2023 | 139.41 Mn |
| Jun 30, 2023 | 155.54 Mn |
| Mar 31, 2023 | 55.63 Mn |
| Dec 31, 2022 | 277.55 Mn |
| Sep 30, 2022 | 163.18 Mn |
| Jun 30, 2022 | 194.77 Mn |
| Mar 31, 2022 | 152.55 Mn |
| Dec 31, 2021 | 172.11 Mn |
| Sep 30, 2021 | 114.51 Mn |